← Back to Clinical Trials
Recruiting NCT05679557

NCT05679557 Comprehensive Geriatric Assessment for Perioperative Optimization in Cystectomy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05679557
Status Recruiting
Phase
Sponsor Aarhus University Hospital
Condition Bladder Cancer
Study Type INTERVENTIONAL
Enrollment 140 participants
Start Date 2023-02-01
Primary Completion 2026-04-01

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Perioperative geriatric assessment and intervention

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 140 participants in total. It began in 2023-02-01 with a primary completion date of 2026-04-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Patients with muscle-invasive bladder cancer are often older and multimorbid, thus in an increased risk of perioperative mortality and morbidity in relation to radical cystectomy (RC). The aim of the study is to investigate the effect of perioperative Comprehensive Geriatric Assessment (CGA) and tailored intervention in older, frail patients with bladder cancer undergoing RC.

Eligibility Criteria

Inclusion Criteria: 1. Patients with muscle-invasive bladder cancer and scheduled radical cystectomy. 2. Planned urinary diversion with an ileal conduit 3. Age ≥ 65 years. 4. Patients considered frail by G8 screening tool (total score ≤14). Exclusion Criteria: 1. Patients who refuse or are not able to provide informed consent. 2. Patients who do not speak or understand Danish. 3. Planned concomitant nephroureterectomy or other major surgical intervention at the same time as RC

Contact & Investigator

Central Contact

Jørgen Bjerggaard Jensen, Prof., DMSc

✉ katans@rm.dk

📞 +45 30915525

Principal Investigator

Jørgen S Bjerggaard Jensen, Prof., DMSc

PRINCIPAL INVESTIGATOR

Aarhus University Hospital and Aarhus University

Frequently Asked Questions

Who can join the NCT05679557 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, studying Bladder Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05679557 currently recruiting?

Yes, NCT05679557 is actively recruiting participants. Contact the research team at katans@rm.dk for enrollment information.

Where is the NCT05679557 trial being conducted?

This trial is being conducted at Odense, Denmark.

Who is sponsoring the NCT05679557 clinical trial?

NCT05679557 is sponsored by Aarhus University Hospital. The principal investigator is Jørgen S Bjerggaard Jensen, Prof., DMSc at Aarhus University Hospital and Aarhus University. The trial plans to enroll 140 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology